John Steuart Joins Prolog Ventures, a Life Science Venture Capital Firm, as Managing Director Reunites with his one-time colleagues Brian Clevinger, Greg Johnson and Ilya Nykin, managing directors and co-founders of Prolog
ST. LOUIS, Feb. 19, 2013 /PRNewswire-iReach/ -- Prolog Ventures, a life science venture capital firm, today named John Steuart as a managing director. He will join managing directors Brian Clevinger, Greg Johnson and Ilya Nykin, who co-founded Prolog in 2000.
Steuart has more than 25 years of experience managing healthcare and technology companies and venture capital funds. He began his investing career at the pioneering venture capital firm Alafi Capital, where for a time he worked closely alongside Brian Clevinger. The two later also collaborated on the leadership team of Megan Health, a spinout of Washington University in St. Louis. Steuart went on to serve as the CFO at two venture-backed public companies before returning to venture capital investing as a co-founder and managing director of Claremont Creek Ventures. His practice at Claremont Creek focused on investing in early stage healthcare companies.
"I am thrilled to be on the same team with John again," said Clevinger. "His investment experience and deal flow networks fit perfectly with Prolog's core areas of focus. All of us here at Prolog are convinced that John's presence will boost our ability to build successful life science ventures."
Steuart expertise in the art and science of venture creation is well-recognized. He is frequently asked to speak at industry events. He serves on the Advisory Boards for the Lester Center of Entrepreneurship and the Center for Entrepreneurship and Technology at UC Berkeley.
"Venture capital as an asset class may have its ups and downs," said Nykin, who first worked with Steuart on a potential co-investment some 20 years ago. "But competition for the very best investment opportunities invariably remains intense. We will be in a stronger position to win them with an investor and entrepreneur of John's stature."
"Nothing is more important in the venture capital business than being on the right investment team," said Steuart. "I have gotten to know my Prolog colleagues over the course of many years. I worked with them, I reviewed investments with them, I am a limited partner in one of their funds. It is the right team for me: experienced, focused, hard-working, with a distinct strategy and emphasis on adding value. I am excited to help the firm build its investment practice into an enduring franchise."
About Prolog Ventures:
Prolog is a life science venture capital firm. Since launching its inaugural fund in 2001, Prolog has partnered with more than 30 early-stage companies. The firm invests in traditional healthcare opportunities as well as selected areas that until recently received little venture capital attention: analytical platforms for diagnostic, industrial and other testing applications; bioscience-based green technology solutions; and consumer nutrition and wellness products. For more information, visit http://www.prologventures.com.
Media Contact: Ilya Nykin Prolog Ventures, +1 (314) 743-2400, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Prolog Ventures